评估多组分治疗对原发性低级别脑胶质瘤进展的有效性。自己的经验。

M. Sarycheva
{"title":"评估多组分治疗对原发性低级别脑胶质瘤进展的有效性。自己的经验。","authors":"M. Sarycheva","doi":"10.17816/onco456888","DOIUrl":null,"url":null,"abstract":"The purpose of the study: to determine the most important prognostic factors, as well as the most effective treatment option in patients with continued growth of primary low-grade gliomas of the brain. Materials and Methods: This study included 40 patients with a confirmed diagnosis of progression of low-malignant glial brain tumors, who underwent inpatient treatment at the Chelyabinsk oncology center from 2007 to 2022. The ratio of men and women: 1:1.5. The mean age was 45.6 11.5 years. Patients with grade I astrocytomas predominated (n=23), oligodendroglioma was diagnosed in 8 patients. Reoperation was performed in 11 patients as the first stage of progression treatment. In 7 cases, monochemotherapy with temozolomide was performed. Repeated radiation therapy was performed in 29 patients, of which: 9 patients received a course of combined photon-neutron therapy ; 9 people stereotactic radiation therapy was performed on the CyberKnife device; in 11 cases - external beam radiation therapy . Results: The median overall survival (OS) for all patients with continued growth of low-grade cerebral gliomas after treatment was 120 months. 1-year OS - 97.3%; 3-year-old - 86.8%; 5-year-old - 78.2%. Median OS after relapse treatment was 36 months. The median OS was higher in the age group under 50 compared to the older age group: 120 and 95 months. (p0.05). The best results of treatment were noted in patients who underwent reoperation followed by a course of radiation therapy or chemotherapy with temozolomide for 48 months. and 36 months. respectively (p0.05). When analyzing the results of treatment after a course of repeated radiation therapy in an independent variant, there were undoubted advantages in patients who underwent stereotactic radiation therapy and photon-neutron therapy for 60 months. and 34 months. (p0.05). Conclusion: Thus, the optimal approach to the treatment of patients with continued growth of primary low-grade glioma brain tumors is to perform a second operation, followed by radiation therapy or chemotherapy. The method of choice for a repeat course of radiotherapy may be photon-neutron therapy or a course of stereotactic radiation therapy. Key words: recurrent , astrocytoma, temozolomide, stereotactic radiation therapy","PeriodicalId":509207,"journal":{"name":"Russian Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the effectiveness of multicomponent treatment in the progression of primary low-grade brain gliomas. Own experience.\",\"authors\":\"M. Sarycheva\",\"doi\":\"10.17816/onco456888\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The purpose of the study: to determine the most important prognostic factors, as well as the most effective treatment option in patients with continued growth of primary low-grade gliomas of the brain. Materials and Methods: This study included 40 patients with a confirmed diagnosis of progression of low-malignant glial brain tumors, who underwent inpatient treatment at the Chelyabinsk oncology center from 2007 to 2022. The ratio of men and women: 1:1.5. The mean age was 45.6 11.5 years. Patients with grade I astrocytomas predominated (n=23), oligodendroglioma was diagnosed in 8 patients. Reoperation was performed in 11 patients as the first stage of progression treatment. In 7 cases, monochemotherapy with temozolomide was performed. Repeated radiation therapy was performed in 29 patients, of which: 9 patients received a course of combined photon-neutron therapy ; 9 people stereotactic radiation therapy was performed on the CyberKnife device; in 11 cases - external beam radiation therapy . Results: The median overall survival (OS) for all patients with continued growth of low-grade cerebral gliomas after treatment was 120 months. 1-year OS - 97.3%; 3-year-old - 86.8%; 5-year-old - 78.2%. Median OS after relapse treatment was 36 months. The median OS was higher in the age group under 50 compared to the older age group: 120 and 95 months. (p0.05). The best results of treatment were noted in patients who underwent reoperation followed by a course of radiation therapy or chemotherapy with temozolomide for 48 months. and 36 months. respectively (p0.05). When analyzing the results of treatment after a course of repeated radiation therapy in an independent variant, there were undoubted advantages in patients who underwent stereotactic radiation therapy and photon-neutron therapy for 60 months. and 34 months. (p0.05). Conclusion: Thus, the optimal approach to the treatment of patients with continued growth of primary low-grade glioma brain tumors is to perform a second operation, followed by radiation therapy or chemotherapy. The method of choice for a repeat course of radiotherapy may be photon-neutron therapy or a course of stereotactic radiation therapy. Key words: recurrent , astrocytoma, temozolomide, stereotactic radiation therapy\",\"PeriodicalId\":509207,\"journal\":{\"name\":\"Russian Journal of Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Russian Journal of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17816/onco456888\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17816/onco456888","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

研究目的:确定脑部原发性低级别胶质瘤持续生长患者最重要的预后因素以及最有效的治疗方案。 材料与方法:研究对象包括 40 名确诊为低恶性胶质脑肿瘤进展期的患者,他们于 2007 年至 2022 年期间在车里雅宾斯克肿瘤中心接受了住院治疗。男女比例为 1:1.5。平均年龄为 45.6 11.5 岁。I级星形细胞瘤患者居多(23人),8名患者被诊断为少突胶质细胞瘤。 11名患者在病情进展的第一阶段接受了再手术治疗。7例患者接受了替莫唑胺单化疗。29 名患者接受了重复放射治疗,其中 9 名患者接受了联合光疗:9名患者接受了一个疗程的光子-中子联合疗法;9名患者使用赛博刀设备进行了立体定向放射治疗;11名患者接受了体外放射治疗。 结果:治疗后低级别脑胶质瘤继续生长的所有患者的中位总生存期(OS)为120个月。1年生存率为97.3%;3年生存率为86.8%;5年生存率为78.2%。复发治疗后的中位生存期为36个月。50岁以下年龄组的中位生存期高于较大年龄组:120个月和95个月。(p0.05). 治疗效果最好的患者是接受了再次手术,然后接受放疗或替莫唑胺化疗,疗程分别为 48 个月和 36 个月(P0.05)。在对重复放疗疗程后的治疗结果进行独立变量分析时,接受立体定向放疗和光子-中子治疗 60 个月和 34 个月的患者无疑具有优势(P0.05)。(p0.05). 结论:因此,治疗原发性低级别胶质瘤脑肿瘤继续生长的患者的最佳方法是进行第二次手术,然后进行放疗或化疗。重复放疗的方法可选择光子-中子疗法或立体定向放疗。 关键词:复发性、星形细胞瘤、替莫唑胺、立体定向放射治疗
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluation of the effectiveness of multicomponent treatment in the progression of primary low-grade brain gliomas. Own experience.
The purpose of the study: to determine the most important prognostic factors, as well as the most effective treatment option in patients with continued growth of primary low-grade gliomas of the brain. Materials and Methods: This study included 40 patients with a confirmed diagnosis of progression of low-malignant glial brain tumors, who underwent inpatient treatment at the Chelyabinsk oncology center from 2007 to 2022. The ratio of men and women: 1:1.5. The mean age was 45.6 11.5 years. Patients with grade I astrocytomas predominated (n=23), oligodendroglioma was diagnosed in 8 patients. Reoperation was performed in 11 patients as the first stage of progression treatment. In 7 cases, monochemotherapy with temozolomide was performed. Repeated radiation therapy was performed in 29 patients, of which: 9 patients received a course of combined photon-neutron therapy ; 9 people stereotactic radiation therapy was performed on the CyberKnife device; in 11 cases - external beam radiation therapy . Results: The median overall survival (OS) for all patients with continued growth of low-grade cerebral gliomas after treatment was 120 months. 1-year OS - 97.3%; 3-year-old - 86.8%; 5-year-old - 78.2%. Median OS after relapse treatment was 36 months. The median OS was higher in the age group under 50 compared to the older age group: 120 and 95 months. (p0.05). The best results of treatment were noted in patients who underwent reoperation followed by a course of radiation therapy or chemotherapy with temozolomide for 48 months. and 36 months. respectively (p0.05). When analyzing the results of treatment after a course of repeated radiation therapy in an independent variant, there were undoubted advantages in patients who underwent stereotactic radiation therapy and photon-neutron therapy for 60 months. and 34 months. (p0.05). Conclusion: Thus, the optimal approach to the treatment of patients with continued growth of primary low-grade glioma brain tumors is to perform a second operation, followed by radiation therapy or chemotherapy. The method of choice for a repeat course of radiotherapy may be photon-neutron therapy or a course of stereotactic radiation therapy. Key words: recurrent , astrocytoma, temozolomide, stereotactic radiation therapy
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信